MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Dscsa Compliance
20 questions · exam conditions
0:00
Dscsa ComplianceQuestion 1 of 20

A pharmacy's DSCSA investigation determines a product is illegitimate. Within what timeframe must the pharmacy notify the FDA?

Within 72 hours of the quarantine being placed on the product.
Within 24 hours of making the determination that the product is illegitimate.
Within 30 days of the initial suspicion.
FDA notification is optional; only trading partner notification is required.
← Back to quizzes

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Dscsa Compliance

Practice Dscsa Compliance in MPJE: Multistate Pharmacy Jurisprudence Examination with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Dscsa Compliance, giving you a quick way to practice the rules, question types, and explanations that matter most for MPJE: Multistate Pharmacy Jurisprudence Examination.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A pharmacy's DSCSA investigation determines a product is illegitimate. Within what timeframe must the pharmacy notify the FDA?

  1. Within 72 hours of the quarantine being placed on the product.
  2. Within 24 hours of making the determination that the product is illegitimate. (correct answer)
  3. Within 30 days of the initial suspicion.
  4. FDA notification is optional; only trading partner notification is required.
Explanation: DSCSA requires that the FDA be notified within 24 hours of a determination that a product is illegitimate -- meaning confirmed to be counterfeit, diverted, stolen, or intentionally adulterated. B correctly states this timeframe. A is incorrect because the 24-hour clock runs from the illegitimacy determination, not from quarantine placement. C is incorrect because 30 days far exceeds the 24-hour requirement. D is incorrect because FDA notification is mandatory upon confirmation of illegitimacy.

Question 2

DSCSA's interoperable, electronic, unit-level tracing system -- sometimes called the electronic track and trace system -- was scheduled for phased implementation. Which of the following best describes what this system ultimately requires?

  1. Manual paper-based tracking of all prescription drug shipments.
  2. A DEA-operated national controlled substance tracking database.
  3. A national electronic system enabling unit-level tracking of individual prescription drug packages through the supply chain using standardized product identifiers. (correct answer)
  4. A state-run system where each state board of pharmacy maintains its own drug tracking records.
Explanation: DSCSA's ultimate goal is an interoperable, electronic, unit-level tracing system that enables all trading partners to trace individual prescription drug packages through the supply chain using standardized product identifiers. C correctly describes this system. A is incorrect because the system is electronic, not paper-based. B is incorrect because DSCSA is an FDA-overseen framework, not a DEA database. D is incorrect because DSCSA creates a national, interoperable framework, not a fragmented state-by-state system.

Question 3

A pharmacy purchases a prescription drug product from a source that provides transaction information and a transaction statement but is not an FDA-registered establishment. Which of the following best describes the DSCSA compliance concern?

  1. Purchasing from a non-authorized trading partner violates DSCSA, regardless of transaction documentation provided. (correct answer)
  2. There is no compliance concern because receiving transaction information and a transaction statement satisfies all DSCSA requirements.
  3. There is a minor compliance concern that can be resolved by contacting the FDA after dispensing.
  4. There is no compliance concern because transaction documentation from any source satisfies DSCSA trading partner requirements.
Explanation: DSCSA requires transactions with authorized trading partners -- entities that are appropriately licensed or registered. Receiving transaction documentation from an unauthorized source does not cure the fundamental DSCSA requirement for authorized trading partners. A correctly identifies this compliance concern. B is incorrect because transaction documentation alone does not satisfy the authorized trading partner requirement. C is incorrect because post-dispensing FDA contact does not resolve a transaction with an unauthorized trading partner. D is incorrect because authorization status is independent of the documentation received.

Question 4

A pharmacy receives a suspect product notification from a trading partner about a lot of an antihypertensive it currently has in stock. The pharmacy has not yet dispensed any units. What is the pharmacy's first required action under DSCSA?

  1. Immediately dispense remaining units before the notification can be formalized.
  2. Quarantine the identified lot immediately to prevent dispensing while conducting a DSCSA investigation with the trading partner. (correct answer)
  3. Return the product to the distributor and request a credit.
  4. File a report with the state board of pharmacy within 24 hours.
Explanation: Upon receiving a suspect product notification, the pharmacy's first required action is to quarantine all units of the identified lot to prevent dispensing while the investigation proceeds. B correctly identifies this immediate obligation. A is incorrect because dispensing after receiving a suspect notification is a serious DSCSA violation. C is incorrect because product return before completing the investigation would eliminate the ability to fulfill DSCSA investigation requirements. D is incorrect because state board notification is not the first required DSCSA action; quarantine and investigation are.

Question 5

A pharmacy receives a salesperson's offer to sell branded prescription drug products directly from a manufacturer's representative at a significant discount, bypassing the usual wholesale distributor. Which of the following best analyzes this offer from a DSCSA perspective?

  1. The pharmacy may purchase directly from the manufacturer because manufacturers are authorized trading partners under DSCSA.
  2. The pharmacy may purchase if the salesperson provides a signed statement confirming the product's legitimacy.
  3. The pharmacy may purchase if the products have current expiration dates.
  4. The pharmacy must verify the manufacturer's authorized trading partner status and obtain required transaction documentation. (correct answer)
Explanation: While manufacturers are authorized trading partners, the specific transaction must still be conducted through authorized channels with the required supply chain documentation -- transaction information and a transaction statement under the current DSCSA enhanced tracing framework. A salesperson conducting an informal direct sale may not represent an authorized transaction channel even if the manufacturer is registered. D correctly identifies the compliance analysis required. A is not fully correct because manufacturer registration does not automatically authorize every sales representative's transaction channel. B is incorrect because a salesperson's signed statement does not satisfy DSCSA documentation requirements. C is incorrect because expiration date does not substitute for required documentation and authorized trading partner verification.

Question 6

A pharmacy discovers it received a prescription drug shipment from an unauthorized wholesale distributor six months ago. The T3 documentation provided at the time appeared complete. Which of the following best describes the pharmacy's compliance situation?

  1. The pharmacy has no compliance concern because the T3 documentation appeared complete at the time of receipt.
  2. The compliance concern is limited to the period in which the unauthorized distributor operated.
  3. The pharmacy is non-compliant due to transactions with an unauthorized distributor, regardless of T3 documentation completeness. (correct answer)
  4. The compliance concern is resolved because six months have passed since the transaction.
Explanation: DSCSA requires purchasing from authorized trading partners. Discovering that a prior distributor was unauthorized creates a compliance concern regardless of the apparent completeness of T3 documentation. The pharmacy should assess the situation, consider FDA notification, and implement corrective measures. C correctly identifies this ongoing compliance obligation. A is incorrect because T3 appearance alone does not satisfy the authorized trading partner requirement. B is incorrect because the compliance concern is not limited by the unauthorized distributor's operational period. D is incorrect because the passage of time does not resolve a DSCSA violation.

Question 7

A pharmacy chain uses a centralized electronic system for supply chain transaction records (transaction information and transaction statements) maintained at corporate headquarters. During a state board inspection of an individual branch, the inspector requests these records. The branch cannot access the corporate system due to a system outage. Which of the following best analyzes the compliance concern?

  1. There is no compliance concern because T3 records are maintained at the corporate level.
  2. There is no compliance concern because system outages are force majeure events that excuse record production.
  3. There is a compliance concern due to inaccessible transaction records during inspection at the branch location. (correct answer)
  4. There is no compliance concern because the inspector should contact corporate headquarters directly for records.
Explanation: DSCSA requires that each dispensing location be able to produce its supply chain transaction records -- transaction information and transaction statements -- upon inspection. A centralized system that is inaccessible at the branch level during an inspection fails this accessibility requirement regardless of the cause. The pharmacy must implement redundancy or contingency measures to ensure records are accessible at each registered location. C correctly identifies the compliance concern. A is incorrect because corporate-level maintenance does not satisfy the branch-level accessibility requirement. B is incorrect because a systemic failure to ensure record accessibility at each location is not excused by force majeure principles; the accessibility obligation is ongoing. D is incorrect because requiring the inspector to contact a third party is not an acceptable substitute for branch-level record production.

Question 8

A pharmacist in a hospital notices that a surgical supply vendor has left a box of fentanyl patches in a medication preparation area. The box has no T3 documentation. Which of the following best applies from a DSCSA and DEA perspective?

  1. The pharmacist may incorporate the fentanyl patches into the hospital's drug supply because a surgical supply vendor is an authorized source.
  2. The pharmacist may use the patches for immediate patient needs and request T3 documentation afterward.
  3. The pharmacist may accept the delivery if the vendor provides a verbal assurance of legitimacy.
  4. The pharmacist must reject the patches; fentanyl requires DSCSA transaction documentation and DEA compliance, and the vendor is unauthorized. (correct answer)
Explanation: This scenario presents dual compliance concerns: DSCSA requires transaction information and a transaction statement from an authorized trading partner for prescription drugs, and DEA regulations impose strict chain-of-custody and ordering requirements for Schedule II controlled substances. A surgical supply vendor is not an authorized DSCSA trading partner for prescription drug distribution, and the absence of proper documentation for a Schedule II controlled substance creates a serious DEA compliance concern as well. D correctly identifies both issues. A is incorrect because surgical supply vendors are not authorized DSCSA trading partners for prescription drugs regardless of any other authorization. B is incorrect because retroactive documentation does not cure an unauthorized transaction or an improperly sourced Schedule II. C is incorrect because verbal assurances do not substitute for required supply chain documentation and DEA compliance.

Question 9

A pharmacy receives a drug shipment and verifies that the T3 documents are complete. The physical packaging of some units shows a slight color variation from what the pharmacist expects. Which of the following best describes the appropriate response?

  1. Accept and dispense the products because complete T3 documentation is the only required verification step.
  2. Quarantine affected units and investigate color variation for potential suspect product. Document findings. (correct answer)
  3. Return the entire shipment to the distributor without documentation.
  4. Accept all products because color variations in packaging are always due to manufacturing lot differences.
Explanation: Complete T3 documentation satisfies the paperwork requirement, but pharmacists also have an obligation to identify suspect products based on physical indicators. Color variation is a potential indicator of counterfeiting requiring quarantine and investigation of affected units. B correctly balances these obligations. A is incorrect because T3 compliance does not override the obligation to investigate physical indicators of suspect product. C is incorrect because returning the entire shipment without investigation and documentation does not satisfy DSCSA requirements. D is incorrect because dismissing color variation as normal without investigation may miss a genuine counterfeiting indicator.

Question 10

Which federal law established the Drug Supply Chain Security Act (DSCSA) framework for tracking and tracing prescription drug products through the supply chain?

  1. The Controlled Substances Act of 1970.
  2. The Drug Quality and Security Act of 2013, Title II of which is the DSCSA. (correct answer)
  3. The Drug Supply Chain Security Act was enacted as standalone federal legislation independent of any other statute in 2013.
  4. The Federal Food, Drug, and Cosmetic Act Amendments of 2007.
Explanation: The DSCSA was enacted as Title II of the Drug Quality and Security Act (DQSA) of 2013. B correctly and precisely identifies this. A is incorrect because the Controlled Substances Act governs controlled substance regulation, not drug supply chain security. C is incorrect because DSCSA was not enacted as standalone independent legislation; it is Title II of the DQSA. D is incorrect because the 2007 FDCA amendments addressed different topics and predated the DSCSA.

Question 11

Under DSCSA, what constitutes the 'product identifier' that must be placed on certain prescription drug packages?

  1. Only the NDC number printed in human-readable text.
  2. Only the manufacturer's lot number.
  3. The manufacturer's name and address only.
  4. A 2D barcode with NDC, serial, lot, and expiration date. (correct answer)
Explanation: DSCSA requires a standardized product identifier on drug packages encoding the NDC, a unique serial number, lot number, and expiration date -- typically in a 2D data matrix barcode format. D correctly identifies these required elements. A is incorrect because the NDC in human-readable text alone does not constitute the full DSCSA product identifier. B is incorrect because lot number alone is insufficient. C is incorrect because manufacturer identification alone does not constitute the product identifier.

Question 12

For how long must a pharmacy retain T3 transaction documents under DSCSA?

  1. Two years from the date of transaction.
  2. One year from the date of transaction.
  3. Three years from the date of transaction.
  4. Six years from the date of transaction. (correct answer)
Explanation: DSCSA requires trading partners including pharmacies to maintain T3 documents for at least six years from the date of the transaction. D correctly states this retention requirement. A is incorrect because two years is the DEA controlled substance records standard, not the DSCSA retention period. B is incorrect because one year is below the DSCSA minimum. C is incorrect because three years is also below the DSCSA six-year requirement.

Question 13

Under DSCSA, which of the following entities are considered authorized trading partners from whom a pharmacy may lawfully receive prescription drug products?

  1. Any entity that holds a valid state business license in the state where it is located.
  2. Any entity that offers prescription drugs at prices below the market average.
  3. Licensed manufacturers, wholesale distributors, repackagers, and dispensers with required T3 documentation. (correct answer)
  4. Any entity that has signed a written distribution agreement with the pharmacy.
Explanation: DSCSA authorizes transactions only with trading partners that are appropriately licensed or registered -- manufacturers, wholesale distributors, repackagers, and dispensers -- and that provide required T3 documentation. C correctly identifies the authorized trading partner framework. A is incorrect because a state business license alone does not make an entity an authorized DSCSA trading partner. B is incorrect because pricing has no bearing on authorized trading partner status. D is incorrect because a written distribution agreement alone does not confer authorized trading partner status under DSCSA.

Question 14

DSCSA requires pharmacies to be able to trace a prescription drug product through the supply chain. What does this tracing capability require a pharmacy to do in practice?

  1. Install a GPS tracking device in each shipment it receives.
  2. Conduct a physical examination of every drug product before accepting each shipment.
  3. Report the location of every drug product it receives to the FDA in real time.
  4. Keep T3 records to trace drug products back through the supply chain when requested. (correct answer)
Explanation: DSCSA tracing capability requires pharmacies to maintain T3 records that can be produced for FDA review or for suspect/illegitimate product investigations, enabling reconstruction of the product's supply chain path. D correctly describes this practical requirement. A is incorrect because GPS tracking is not a DSCSA requirement. B is incorrect because physical examination of every product is not a DSCSA-mandated tracing requirement. C is incorrect because real-time location reporting to the FDA is not required under DSCSA.

Question 15

A pharmacy's DSCSA investigation cannot verify a product's legitimacy because the trading partner is unresponsive to investigation requests over a two-week period. What must the pharmacy do?

  1. Release the product from quarantine because the investigation has been ongoing for two weeks without resolution.
  2. Maintain quarantine and notify the FDA and trading partners of the verification issue. (correct answer)
  3. Dispense the product in small quantities while continuing the investigation.
  4. Notify the state board of pharmacy and await their guidance before any further action.
Explanation: When a pharmacy cannot verify a product's legitimacy after reasonable investigation efforts -- including an unresponsive trading partner -- DSCSA requires maintaining the quarantine and escalating to the FDA and affected trading partners. Inability to verify legitimacy is not a legal determination that the product is illegitimate, but it is sufficient reason to keep the product out of the supply chain until legitimacy can be established. B correctly identifies this risk-based approach. A is incorrect because passage of time alone does not authorize release from quarantine; the legitimacy question must be resolved. C is incorrect because dispensing a product with unresolved legitimacy concerns violates DSCSA. D is incorrect because state board notification is not the required DSCSA response; FDA and trading partner escalation is the applicable framework.

Question 16

A pharmacy's supply chain compliance officer asks whether DSCSA applies to all drug products the pharmacy receives, or only to certain categories. Which of the following best describes DSCSA's scope?

  1. DSCSA applies to all drug products including vitamins, supplements, and OTC products.
  2. DSCSA applies to prescription drugs, excluding OTC products, blood, supplements, and certain exempted categories. (correct answer)
  3. DSCSA applies only to Schedule II controlled substances distributed through the supply chain.
  4. DSCSA applies only to biologics and biosimilars.
Explanation: DSCSA applies to prescription drug products as defined under the FDCA. Several product categories are exempted, including OTC products, blood and blood components, dietary supplements, radiopharmaceuticals, and certain other products. B correctly identifies this scope. A is incorrect because OTC products, supplements, and vitamins are generally not subject to DSCSA. C is incorrect because DSCSA is not limited to Schedule II controlled substances; it applies broadly to all prescription drug products across all drug schedules and non-controlled Rx products. D is incorrect because DSCSA applies beyond biologics and biosimilars to all prescription drug products meeting the FDCA definition.

Question 17

Under DSCSA, a pharmacy that is transferring ownership of its prescription drug inventory to a new pharmacy must provide which of the following to the receiving pharmacy?

  1. Only a bill of sale listing the drugs and prices.
  2. Only the DEA registration number of the transferring pharmacy.
  3. Transaction information and statement for all transferred prescription drugs. (correct answer)
  4. Only a signed inventory sheet attesting to the condition of the drugs.
Explanation: When prescription drug products are transferred between pharmacies, the transferring pharmacy must provide transaction information and a transaction statement -- the currently required DSCSA supply chain documentation -- for all products being transferred. The receiving pharmacy must maintain these records for the required retention period. C correctly identifies this requirement. A is incorrect because a bill of sale alone does not constitute DSCSA-compliant supply chain documentation. B is incorrect because the DEA registration number alone is not sufficient supply chain documentation. D is incorrect because a condition attestation does not satisfy DSCSA requirements.

Question 18

What information must be included in the Transaction Information (TI) under DSCSA?

  1. Only the drug name and lot number.
  2. Only the manufacturer's name and the distributor's DEA registration number.
  3. Drug name, strength, dosage form, NDC, lot number, transaction and shipment dates. (correct answer)
  4. Only the transaction date and the NDC number.
Explanation: DSCSA requires Transaction Information to include specific product identification details -- name, strength, dosage form, NDC number, container size, number of containers, lot number -- along with transaction and shipment dates, and the business name and address of both the transferring party and the receiving party. C correctly identifies these comprehensive requirements. A is incorrect because drug name and lot number alone are far below the required TI content. B is incorrect because manufacturer name and DEA number alone do not satisfy TI requirements. D is incorrect because transaction date and NDC number alone are also insufficient.

Question 19

What is the Transaction Statement (TS) in the context of DSCSA T3 documentation?

  1. A certification of authorized trading partner product compliance. (correct answer)
  2. A government-issued certificate confirming a product's FDA approval.
  3. A patient-specific label generated at the time of dispensing.
  4. An FDA inspection report confirming the product's manufacturing compliance.
Explanation: The Transaction Statement is the trading partner's written attestation that the product was received from authorized trading partners, is not suspect or illegitimate, has not been detained or recalled, is not a counterfeit, and was handled in compliance with DSCSA. A correctly identifies this certification function. B is incorrect because the TS is a private trading partner certification, not a government-issued document. C is incorrect because a dispensing label is not a T3 document. D is incorrect because FDA inspection reports are separate regulatory documents.

Question 20

Under DSCSA's product verification requirements, which of the following represents an obligation for pharmacies when dispensing prescription drug products?

  1. Pharmacies must verify the 2D barcode on every unit dispensed to a patient.
  2. Pharmacies must submit verification reports to the FDA for every product dispensed.
  3. Pharmacies must verify product identifiers for suspect products or when directed by the FDA. (correct answer)
  4. Pharmacies must send verification requests to the manufacturer for every controlled substance dispensed.
Explanation: DSCSA's verification requirements for dispensers are triggered by suspect product identification or FDA/trading partner direction, not routine unit-level verification of every dispensed product. Routine verification is not required for standard dispensing operations at the pharmacy level. C correctly describes this targeted rather than universal verification obligation. A is incorrect because routine 2D barcode verification of every dispensed unit is not required under current DSCSA dispenser requirements. B is incorrect because dispensing reports to the FDA are not required for every product. D is incorrect because manufacturer verification is not required for every controlled substance dispensed.